Brain metastases in patients with salivary duct carcinoma: A retrospective study.
androgen receptor
brain metastases
distant metastases
human epidermal growth factor receptor 2
salivary duct carcinoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
19
12
2023
received:
03
07
2023
accepted:
02
01
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
ppublish
Résumé
Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with a 5-year survival rate of 40%. Although drug therapy has improved patients' prognosis, the impact of brain metastasis (BM) remains poorly understood. We aimed to retrospectively examine the incidence of BM in patients with SDC (n = 464) and develop a tool to estimate their prognoses. We retrospectively examined 464 patients with SDC enrolled in a multicenter study. We investigated the incidence of BM, overall survival (OS) rates, and factors affecting prognosis in patients with BM. We also developed an SDC-graded prognostic assessment (GPA) score for disease prognostication. Sixty-five (14%) patients had BM. The median OS (mOS) was 13.1 months. On univariate and multivariate analyses, factors such as Eastern Cooperative Oncology Group Performance Status >1, human epidermal growth factor receptor 2-negative status, and locoregional uncontrolled disease were associated with poor OS. SDC-GPA scores according to the prognostic factors were 0, 1, 2, and 3 points, and mOS estimates were 50.5, 16.1, 3.9, and 1.2 months, respectively (p < 0.001). The SDC-GPA score emerged as a useful prognostication tool for patients with BM.
Sections du résumé
BACKGROUND
BACKGROUND
Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma with a 5-year survival rate of 40%. Although drug therapy has improved patients' prognosis, the impact of brain metastasis (BM) remains poorly understood. We aimed to retrospectively examine the incidence of BM in patients with SDC (n = 464) and develop a tool to estimate their prognoses.
METHODS
METHODS
We retrospectively examined 464 patients with SDC enrolled in a multicenter study. We investigated the incidence of BM, overall survival (OS) rates, and factors affecting prognosis in patients with BM. We also developed an SDC-graded prognostic assessment (GPA) score for disease prognostication.
RESULTS
RESULTS
Sixty-five (14%) patients had BM. The median OS (mOS) was 13.1 months. On univariate and multivariate analyses, factors such as Eastern Cooperative Oncology Group Performance Status >1, human epidermal growth factor receptor 2-negative status, and locoregional uncontrolled disease were associated with poor OS. SDC-GPA scores according to the prognostic factors were 0, 1, 2, and 3 points, and mOS estimates were 50.5, 16.1, 3.9, and 1.2 months, respectively (p < 0.001).
CONCLUSION
CONCLUSIONS
The SDC-GPA score emerged as a useful prognostication tool for patients with BM.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7037Subventions
Organisme : JSPS Grants-in-Aid for Scientific Research (C)
ID : 20K07417
Organisme : JSPS Grants-in-Aid for Scientific Research (C)
ID : 20K07597
Organisme : JSPS Grants-in-Aid for Scientific Research (C)
ID : 21K09616
Organisme : JSPS Grants-in-Aid for Scientific Research (C)
ID : 21K16835
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ. The fourth edition of the head and neck World Health Organization blue book: editors' perspectives. Hum Pathol. 2017;66:10-12.
Lewis AG, Tong T, Maghami E. Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin N Am. 2016;49:343-380.
Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020;18:873-898.
Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 2021;39(17):1909-1941.
Sood S, McGurk M, Vaz F. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130:S142-S149.
Otsuka K, Imanishi Y, Tada Y, et al. Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients. Ann Surg Oncol. 2016;23(6):2038-2045.
Boon E, Bel M, van Boxtel W, et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer. 2018;143(4):758-766.
Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T. Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol. 2020;128(10):693-703.
Santana T, Pavel A, Martinek P, et al. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Hum Pathol. 2019;93:37-47.
Takase S, Kano S, Tada Y, et al. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 2017;8(35):59023-59035.
Masubuchi T, Tada Y, Maruya S, et al. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol. 2015;20(1):35-44.
Jhaveri KL, Wang XV, Makker V, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann Oncol. 2019;30:1821-1830.
Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125-134.
Uijen MJM, Lassche G, van Engen-van Grunsven ACH, et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review. Cancer Treat Rev. 2020;89:102069.
Kurzrock R, Bowles DW, Kang H, et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020;31:412-421.
Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29:979-984.
Mimica X, McGill M, Hay A, et al. Distant metastasis of salivary gland cancer: incidence, management, and outcomes. Cancer. 2020;126:2153-2162.
Messing I, Goyal S, Sherman JH, et al. Incidence and prognosis of brain metastases in head and neck cancer patients at diagnosis. Laryngoscope. 2021;131(9):E2543-E2552.
Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol. 2010;96(1):17-32.
Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290-3297. doi:10.1200/Jco.2018.78.3118
Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722-730.
Yang JCH, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2020;38:538-547.
Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655-663.
Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387-395.
Wolf A, Kvint S, Chachoua A, et al. Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery. J Neurosurg. 2018;128:23-31.
Lau R, Fernández-Coello A, Vidal-Sarró N, et al. Brain metastasis of carcinoma ex pleomorphic adenoma of the parotid gland: case report and review of the literature. Acta Neurochir. 2017;159:459-463.
Venteicher AS, Walcott BP, Sheth SA, et al. Clinical features of brain metastasis from salivary gland tumors. J Clin Neurosci. 2013;20:1533-1537.
Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419-425.
Nagao T, Lictra L, Loening T. Salivary duct carcinoma in WHO classification of head and neck tumours. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, eds. International Agency for Research on Cancer. Volume 9. IARC Publications; 2017:173-174.
Nakaguro M, Sato Y, Tada Y, et al. Prognostic implication of histopathologic indicators in salivary duct carcinoma: proposal of a novel histologic risk stratification model. Am J Surg Pathol. 2020;44:526-535.
Benchetrit L, Mehra S, Mahajan A, Rahmati RW, Judson BL, Edwards HA. Major salivary gland cancer with distant metastasis upon presentation: patterns, outcomes, and imaging implications. Otolaryngol Head Neck Surg. 2022;167(2):305-315.
Sperduto PW, Mesko S, Li J, et al. Beyond an updated graded prognostic assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol Phys. 2020;107:334-343.
Cavalieri S, Nuzzolese I, Ottini A, et al. HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients. Front Oncol. 2023;12:1096068.
Moy B, Rumble RB, Come SE, et al. Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update. J Clin Oncol. 2021;39:3938-3958.
Kawakita D, Nagao T, Takahashi H, et al. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. Ther Adv Med Oncol. 2022;14:17588359221119538.
Nagao T, Gaffey TA, Visscher DW, et al. Invasive micropapillary salivary duct carcinoma: a distinct histologic. Am J Surg Pathol. 2004;28(3):319-326.
Batsakis JG, El-Naggar AK, Luna MA. “Adenocarcinoma, not otherwise specified”: a diminishing group of salivary carcinomas. Ann Otol Rhinol Laryngol. 1992;101(1):102-104.